Table 1.

Immunobridging analysis using a logistic regression model based on data from NHPs vaccinated with the Ad26.ZEBOV, MVA-BN-Filo vaccine regimen in a 56-day interval; PPI analysis set.

Participants Vaccinated, N	764
Pre-planned Immunobridging Analysis
Mean Predicted Survival Probability, % (95% CI)	53.4 (36.7–67.4)
Post-hoc Analysis
Mean Predicted Survival Probability, % (98.7% CI)	53.4 (33.8–70.9)
O’Brien-Fleming Adjustment (One-sided Alpha of 0.0066)

CI confidence interval, NHP non-human primate, PPI per-protocol immunogenicity.

This analysis was based on the pooled data of healthy adults (aged 18-50 years) vaccinated with Ad26.ZEBOV, MVA-BN-Filo in a 56-day interval in five clinical studies (EBL2001, EBL2002, EBL3001, EBL3002, and EBL3003) using a logistic regression model based on NHP data from the Ad26.ZEBOV, MVA-BN-Filo vaccine regimen in a 56-day interval.